23 March 2015
EMA/CHMP/148199/2015
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Agenda of meeting to be held on 23-26 March 2015

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

23 March 2015, 13:00 – 19:30, room 2A

24 March 2015, 08:30 – 19:30, room 2A

25 March 2015, 08:30 – 19:30, room 2A

26 March 2015, 08:30 – 16:00, room 2A

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Health & Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health & safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the applicant details are published as this information is already publicly available.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5505
Send a question via our website www.ema.europa.eu/contact

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

For adoption

Agenda (EMA/CHMP/148199/2015 Rev.4) and Annex to CHMP agenda of the CHMP plenary session to be held 23-26 March 2015
Timeschedule (EMA/CHMP/169219/2015 Rev.3) of the CHMP plenary session to be held 23-26 March 2015
Minutes (EMA/CHMP/158074/2015) of the CHMP plenary session held 23-26 February 2015
Minutes of ORGAM meeting held on 16 March 2015 (EMA/CHMP/181631/2015).

For information

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 23-26 March 2015.	*See March 2015 Minutes (to be published post April 2015 CHMP meeting)*
The Committee is asked to note that Tuomo Lapveteläinen was appointed as the new Alternate from Finland replacing Janne Komi in this role.	
Draft Agenda of CHMP meeting to be held on 20-23 April 2015.	

Table of contents

1. Oral explanations

1.1. Pre-authorisation procedure oral explanations

(EMEA/H/C/002739), (human alpha1-proteinase inhibitor),(treatment of lung disease). List of Outstanding Issues adopted on 20.11.2014. List of Questions adopted on 25.04.2014.	Oral explanation to be held on Wednesday 25 March at 09.00.
(EMEA/H/D/002831), (insulin-like growth factor 1 segment), (hard-to-heal wounds, primarily venous leg ulcers) List of Outstanding Issues adopted on 25.09.2014. List of Questions adopted on 23.01.2014.	Oral explanation to be held on Wednesday 25 March 2015 at 11.00.
(EMEA/H/C/002772), Orphan, (dasiprotimut-t), Applicant: Biovest Europe Ltd, (treatment of non-Hodgkin's lymphoma (FL)) List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.	Oral explanation to be held on Tuesday 24 March 2015 at 14.00.

1.2. Re-examination procedure oral explanation

1.3. Post-authorisation procedure oral explanation

1.4. Referral procedure oral explanation

2. Initial applications

2.1. Initial applications; Opinions –

(EMEA/H/C/003728), (netupitant / palonosetron), (prevention of chemotherapy-induced nausea and vomiting (CINV)) List of Outstanding Issues adopted on 22.01.2015. List of Questions adopted on 22.05.2014.

(EMEA/H/C/003852), (human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed)), (treatment of HPV diseases), List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 24.07.2014.

(EMEA/H/C/003727), Orphan, (lenvatinib), Applicant: Eisai Ltd, (treatment of papillary thyroid cancer, treatment of follicular thyroid cancer). List of Questions adopted on 22.01.2015.

(EMEA/H/C/003985), (nivolumab), (treatment of advanced (unresectable or metastatic) melanoma in adults)
List of Questions adopted on 22.01.2015.

(EMEA/H/C/003770), (empagliflozin / metformin), (treatment of type II diabetes)
List of Questions adopted on 20.11.2014.

EMEA/H/C/003737), (voriconazole), (treatment of fungal infections), List of Outstanding Issues adopted on 20.11.2014.
List of Questions adopted on 24.07.2014.

2.2. Initial applications; Day 180 List of outstanding issues –

(EMEA/H/C/004008), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)
List of Questions adopted on 20.11.2014.

(EMEA/H/C/003904), (atazanavir / cobicistat), (treatment of HIV-1 infected, combination with other antiretroviral medicinal products)
List of Questions adopted on 20.11.2014.

(EMEA/H/C/003984), (bortezomib), (treatment of multiple myeloma)
List of Questions adopted on 23.10.2014.

(EMEA/H/C/003925), (docetaxel), (treatment of breast cancer, non small cell lung cancer, prostate cancer, metastatic gastric adenocarcinoma and head and neck cancer)
List of Questions adopted on 23.10.2014.

(EMEA/H/C/003981), (duloxetine), (treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, treatment of major depressive episodes, diabetic peripheral neuropathic pain and generalised anxiety disorder). List of Questions adopted on 22.01.2015.

(EMEA/H/C/003725), Orphan, (panobinostat), Applicant: Novartis Pharmaceuticals UK Limited, (treatment of multiple myeloma). List of Questions adopted on 25.09.2014.

(EMEA/H/C/003776), (ferric citrate coordination complex), (treatment of hyperphosphataemia)
List of Questions adopted on 24.07.2014.

(EMEA/H/C/003759), (guanfacine), (treatment of ADHD)
List of Questions adopted on 24.07.2014.

(EMEA/H/C/004010), (pregabalin), (treatment of neuropathic pain, epilepsy and generalised anxiety disorder)
List of Questions adopted on 18.12.2014.

(EMEA/H/C/004070), (pregabalin), (treatment of epilepsy and generalised anxiety disorder (GAD))
List of Questions adopted on 18.12.2014.

(EMEA/H/C/003900), (pregabalin), (treatment of epilepsy and Generalised Anxiety Disorder (GAD))
List of Questions adopted on 18.12.2014.

(EMEA/H/C/003794), Orphan, (asfotase alfa), Applicant: Alexion Europe SAS, (treatment of paediatric-onset hypophosphatasia)
List of Questions adopted on 20.11.2014.

(EMEA/H/C/002801), Orphan, ATMP, (allogeneic t cells genetically modified to express suicide gene), Applicant: MolMed SpA, (treatment in haploidentical haematopoietic stem cell transplantation)
List of Questions adopted on 24.07.2014.

2.3. Initial applications; Day 120 List of Questions

(EMEA/H/C/004038), Orphan, (mercaptamine), Applicant: Lucane Pharma, (treatment of corneal cystine deposits)

(EMEA/H/C/002611), (levodopa / carbidopa), (treatment of Parkinson's disease)

(EMEA/H/C/003861), Orphan, (parathyroid hormone), Applicant: NPS Pharma Holdings Limited, (treatment of hypoparathyroidism)

(EMEA/H/C/004071), Orphan, (dexamethasone acetate), Applicant: LABORATOIRES CTRS, (treatment of symptomatic multiple myeloma in combination with other medicinal products.)

- Similarity assessment report : **For adoption**

(EMEA/H/C/003860), (mepolizumab), (treatment of asthma)

(EMEA/H/C/003954), Orphan, (lumacaftor / ivacaftor), Applicant: Vertex Pharmaceuticals (U.K.) Ltd., (treatment of cystic fybrosis)

(EMEA/H/C/004072), (pemetrexed), (unresectable malignant pleural mesothelioma metastatic non-small cell lung cancer)

2.4. Update on on-going initial applications for Centralised procedure

(EMEA/H/C/003964), Orphan, (Efmoroctocog Alfa), Applicant: Biogen Idec Ltd, (treatment of Haemophilia A)

Heparesc (EMEA/H/C/003750), Orphan, ATMP, (allogenic human heterologous liver cells), Applicant: Cytonet GmbH&Co KG, (treatment of urea cycle disorders (UCD)), List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.

- Update on CAT discussion: **For information**

(EMEA/H/C/003774), (selexipag), (treatment of pulmonary arterial hypertension (PAH; WHO Group I)

- Similarity assessment report: **For adoption**

(EMEA/H/C/003926), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)

2.5. Products in the Decision Making Phase

Mysimba (EMEA/H/C/003687), (naltrexone / bupropion), Applicant: Orexigen Therapeutics Ireland Limited, (indicated for the management of obesity)
Fixed combination application (Article 10b of Directive No 2001/83/EC). Opinion adopted on 18.12.2014.

3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

3.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinions

3.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 List of outstanding issues

Norvir (EMEA/H/C/000127/X/0127), (ritonavir), MAH: AbbVie Ltd., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Sabine Straus, “The MAH applies for a line extension of a new oral powder formulation of Norvir (ritonavir) as a replacement for the currently marketed Norvir oral solution for a more suitable ritonavir formulation for the paediatric population.”
List of Questions adopted on 23.10.2014.

3.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of Questions

Mabthera (EMEA/H/C/000165/X/0101/G), (rituximab), MAH: Roche Registration Ltd, Rapporteur: Christian Schneider, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Doris Stenver, "Grouping of:
- Line extension to add a new strength 1600 mg solution for subcutaneous injection, a new indication is proposed for this strength (different from 1400mg strength).
- Type II variation to update the product information of the existing strengths as a consequence to the line extension application
- Type II variation to update the RMP"

3.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No item

4. Type II variations - Extension of indication procedures according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Type II variation; Extension of indication- Opinions or Requests for supplementary information -

Fycompa (EMEA/H/C/002434/II/0016), (perampanel), MAH: Eisai Europe Ltd., Rapporteur: Robert James Hemmings, Co-Rapporteur: Pierre Demolis, PRAC Rapporteur: Julie Williams, "Extension of indication as adjunctive treatment of Primary Generalised Tonic-Clonic seizures in patients with epilepsy aged 12 years and older. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to propose minor changes to PL and update the contact details of the Maltese local representative." Request for Supplementary Information adopted on 18.12.2014.

Levemir (EMEA/H/C/000528/II/0070), (insulin detemir), MAH: Novo Nordisk A/S, Rapporteur: Jens Heisterberg, "Update of sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to extend the clinical use of Levemir in children from 2 years to 1 year of age. The Package Leaflet is updated accordingly."
Qutenza (EMEA/H/C/000909/II/0039), (capsaicin), MAH: Astellas Pharma Europe B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Magda Pedro, "Extension of indication to include treatment of diabetic patients with peripheral neuropathic pain based on the results of studies E05-CL-3004 (STEP) and E05-CL-3002 (PACE). As a consequence sections 4.1, 4.4 and 4.8 of the SmPC have been updated, and Annex II (additional risk minimisation measures) and the Package Leaflet have been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC, Annex II, labelling and Package Leaflet. An updated RMP (version 18) was provided as part of the application. The provision of studies STEP and PACE addresses MEA 001.4."
Rebetol (EMEA/H/C/000246/II/0074), (ribavirin), MAH: Merck Sharp & Dohme Limited, Rapporteur: Joseph Emmerich, "Change of the indication of Rebetol to reflect that ribavirine is indicated in the treatment of hepatitis C in combination with other medicinal products and remove reference to the peginterferon used (2a or 2b) in line with the PRAC recommendation in the PSUR assessment (EMEA/H/C/PSUSA/000100007/201307). As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.7, 4.8, 4.9 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly." Request for Supplementary Information adopted on 23.10.2014.

Relistor (EMEA/H/C/000870/II/0030), (methylnaltrexone bromide), MAH: TMC Pharma Services Ltd, Rapporteur: Harald Enzmann, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Valerie Strassmann, "The MAH applied for an extension of the indication for the treatment of opioid induced constipation in adult non cancer pain patients. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.4 and 5.1 of the SmPC. The Package Leaflet was proposed to be updated in accordance."
Request for Supplementary Information adopted on 20.11.2014, 26.06.2014.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Revlimid (EMEA/H/C/000717/II/0079), Orphan, (lenalidomide), MAH: Celgene Europe Limited, Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Arnaud Batz, "Extension of Indication to add treatment of adult patients with relapsed and/ or refractory mantle cell lymphoma (MCL). As a consequence, SmPC sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC and Package Leaflet. A revised version of the RMP (version 25.0) was provided as part of this application."

Tamiflu (EMEA/H/C/000402/II/0110/G), (oseltamivir), MAH: Roche Registration Ltd, Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Bruno Sepodes, "A group of a type II extension of indication to include the treatment of influenza in infants below one year of age and a type IAIN to add a 3 ml plastic oral dispenser (for the Tamiflu 6mg/ml strength)"
Request for Supplementary Information adopted on 23.10.2014.

Tygacil (EMEA/H/C/000644/II/0092), (tigecycline), MAH: Pfizer Limited, Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Miguel-Angel Macia, "Addition of a new restricted indication in children eight year-old and older. The sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated accordingly. The Package Leaflet is also updated. In addition, an updated RMP is proposed."

Volibris (EMEA/H/C/000839/II/0041), Orphan, (ambrisentan), MAH: Glaxo Group Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Radka Montoniová, PRAC Rapporteur: Dolores Montero Corominas, "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to include an expanded therapeutic indication for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)
In addition, the MAH took the opportunity to update Annex II to reflect a change in the PSUR cycle. The Package leaflet is proposed to be updated accordingly."

XALKORI (EMEA/H/C/002489/II/0024), (crizotinib), MAH: Pfizer Limited, Rapporteur: Pierre Demolis, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Arnaud Batz, "Type II variation to apply for extension of XALKORI indication to the first-line treatment ALK-positive advanced NSCLC (section 4.1 of the SmPC) and to update sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the XALKORI SmPC to
include results of the pivotal Study A8081014, a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of crizotinib to first-line chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) in patients with previously untreated ALK-positive advanced non-squamous NSCLC and updated safety results from Studies A8081001, A8081005 and A8081007. In addition, section 5.1 of the SmPC was revised to include updated overall survival data from Studies A8081001 and A8081005."

Xultophy (EMEA/H/C/002647/II/0002), (insulin degludec / liraglutide), MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Menno van der Elst, "Extension of indication for Xultophy to include transfer of patients from Glucagon-Like peptide-1 (GLP1) receptor agonist (RA) treatment to Xultophy. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.4, and 5.1 of the SmPC. The Package Leaflet is updated accordingly."

4.2. Update on on-going type II variation; extension of indications

Vidaza (EMEA/H/C/000978/II/0030), Orphan, (azacitidine), MAH: Celgene Europe Limited, Rapporteur: Pieter de Graeff, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Sabine Straus, "Extension of Indication to add treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification, based on the pivotal phase III study AZA- AML-001. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. A revised RMP version 10.0 was provided as part of the application. The application includes a request for an additional year of market protection for a new indication in accordance with Article 10(1) of Directive 2001/83/EC."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).

- Similarity assessment report : **For adoption**

5. Ancillary medicinal substances in medical devices

5.1. Ancillary medicinal substances in medical devices - Opinions/ List of outstanding issues / List of Questions

6. Re-examination procedure (new applications) under Article 9(2) of Regulation no 726/2004

No item

7. Re-examination procedure (Type II variations) under Article 16 of Commission Regulation (EC) No 1234/2008 and 9(2) of Regulation (EC) No 726/2004

No item

8. Withdrawal of initial application

No item

9. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No item

10. Pre-submission issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

No item

11. Post-authorisation issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

BSWP response to letter regarding Kinetica software used in BE studies

Rienso (EMEA/H/C/002215)
(Ferumoxytol), MAH: Takeda Pharma A/S, Rapporteur: Harald Enzmann, Co-Rapporteur: Romaldas Mačiulaitis, (treatment of iron deficiency with chronic kidney disease (CKD)), New active substance (Article 8(3) of Directive No 2001/83/EC).

Ad-hoc Influenza Working Group: EU Strain selection for the Influenza Vaccines for the Season 2015/2016, **For adoption** • EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2015/2016: **For adoption** • Report from the Ad Hoc Influenza working group to the BWP: **For adoption**	
Xarelto (EMEA/H/C/000944/II/0038), (rivaroxaban), MAH: Bayer Pharma AG, Rapporteur: Kristina Dunder, , "Submission of study results (EINSTEIN cancer analysis) and literature data on the efficacy and safety of rivaroxaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEp) in patients with active cancer as requested by CHMP in December 2014 during variation II-33." • Request for supplementary information or Opinion: **For adoption**	
Simponi (EMEA/H/C/000992/II/0063), (golimumab), MAH: Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of the SmPC sections 4.2 and 5.1 in order to reflect the data from a multicentre, placebo-controlled, double-blind, randomised-withdrawal, parallel group study (GO KIDS) in children (2 to 17 years of age) with active polyarticular juvenile idiopathic arthritis (pJIA). The Package leaflet is proposed to be updated accordingly. This procedure includes also an update to the RMP." • Request for supplementary information or Opinion: **For adoption**	
Rotarix (EMEA/H/C/000639/II/0062), (human rotavirus, live attenuated), MAH: GlaxoSmithKline Biologicals S.A., Rapporteur: Daniel Brasseur, PRAC Rapporteur: Jean-Michel Dogné, "To submit the final report of genetic stability study EPI-ROTA-014 VS BE – 112560 that addresses the Post-Approval Measure ME2 005.2 in which the MAH commits to monitor for the potential occurrence of genetic drifts and shifts in the vaccine strain in post-marketing settings." Request for Supplementary Information adopted on 24.07.2014, 20.03.2014.	PRAC led variation

Yondelis (EMEA/H/C/000773/S/0042), Orphan, (trabectedin), MAH: Pharma Mar, S.A., Rapporteur: Christian Schneider, PRAC Rapporteur: Torbjorn Callreus,

- Request for supplementary information or Opinion: **For adoption**

Insuman (EMEA/H/C/000201) (Insulin Human), MAH: Sanofi-aventis Deutschland GmbH, Rapporteur: Bart Van der Schueren, Co-Rapporteur: Pieter de Graeff, (treatment of diabetes mellitus), Complete application (stand-alone) - Council Directive 81/851/EEC

12. Referral procedures

12.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

No item

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

No item

12.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No item

12.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

MERISONE 50 mg and 150 mg film coated tablets and MYOSON 50 mg and 150 mg film coated tablet (EMEA/H/A-29/1411)
(tolperisone)
Applicant /MAH: Meditop Pharmaceutical Co.Ltd.
Rapporteur: Agnes Gyurasics , Co-Rapporteur: Johann Lodewijk Hillege, RMS: HU, CMS: DE, NL, BE, LU, Mutual recognition procedures: HU/H/0373/001-002/MR and HU/H/0377/001-002/MR

Scope: Lack of bioequivalence studies to evaluate the food effect.

List of Questions adopted 22.01.2015.

- List of Outstanding Issues: **For adoption**
- PKWP response to CHMP question on Article 29(4) referral for Merisone and Myoson (tolperisone): **For adoption**

IOGOL and associated names soft capsules, 25 / 50 mg (EMEA/H/A-29/1414)
(diclofenac epolamine); Applicant: Regiomedica GmbH
RMS: DE, CMS: AT, BE, CZ, EL, ES, HU, IT, PL, SK, UK, Decentralised procedure number: DE/H/3633/002-003/DC

Scope: Disagreements regarding the demonstration of bioequivalence with the reference product

- Letter from BfARM in Germany dated 6 March 2015 notifying of an official referral under Article 29 (4) and its grounds: **For information**
- Appointment of (Co) Rapporteur: **For discussion**
- List of Questions: **For adoption**
- Timetable: **For adoption**

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Ikorel / Dancor and associated names (EMEA/H/A-30/1380)
(nicorandil), Sanofi-Aventis group of companies and associated companies / Merck group of companies and associated companies, Rapporteur: Joseph Emmerich, Co-Rapporteur: Pieter de Graeff,

Ikorel / Dancor was included in the list of products for SmPC harmonisation, drawn up by the CMDh, in accordance with Article 30(2) of Directive 2001/83/EC. List of Outstanding Issues adopted 22.01.2015

- Opinion: **For adoption**

Haldol and associated names (EMEA/H/A-30/1393) (haloperidol), Janssen-Cilag Group of companies and associated companies
Rapporteur: Martina Weise, Co-Rapporteur: Ivana Mikacic,

- List of Outstanding Issues: **For adoption**

Haldol decanoate and associated names (EMEA/H/A-30/1405) (haloperidol) Janssen-Cilag Group of companies and associated companies
Rapporteur: Martina Weise, Co-Rapporteur: Ivana Mikacic,

- List of Outstanding Issues: **For adoption**

Novantrone and associated names (EMEA/H/A-30/1399)
mitoxantrone), MEDA group of companies and associated companies.
Rapporteur: Pieter de Graeff, Co-Rapporteur: Robert Hemmings,
Harmonisation exercise for Novantrone and associated names. The review was triggered by the European Commission, due to the need of harmonisation of the Summary of Product Characteristics across Member States.

- List of Outstanding Issues : **For adoption**

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

Gadolinium containing contrast agents, Gd-Cas (EMEA/H/A-31/1097)
Rapporteur: Rafe Suvarna, Co-Rapporteur: Pieter de Graeff,

- Letter from the MAH dated 5 March 2015 requesting a delay for the submission of FUM 001 related to study evaluating the potential for long-term retention of gadolinium in bone until 11 May 2015.: **For information**

12.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

GVK Biosciences (EMEA/H/A-31/1408) Rapporteur: Harald Enzmann, Co-Rapporteur: Christian Schneider, Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India following critical GCP deficiencies reported during an inspection performed by the ANSM (Agency for Medicines and Health Products Safety, France) on 19-23 May 2014. Opinion adopted on 22.01.2015. • Appointment of Re-examination (Co)Rapporteur: **Adopted by written procedure**	Hubert Leufkens was appointed as the Re-examination Rapporteur and Karsten Bruins Slot as the Re-examination Co-Rapporteur on 12 March 2015.

12.8. Procedure under Article 107(2) of Directive 2001/83/EC

No item

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

No item

12.10. Procedure under Article 29 Regulation (EC) 1901/2006

No item

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No item

13. Pharmacovigilance issues

Summary of recommendations and advice of PRAC meeting held on 9-12 March 2015: **For information**
List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2015: **For adoption**

Early Notification System:
March 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **for information**

Gilenya (EMEA/H/C/002202)
(Fingolimod Hydrochloride), MAH: Novartis Europharm Ltd, Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson, (treatment of multiple sclerosis), New active substance (Article 8(3) of Directive No 2001/83/EC).

Signal of occurrence of one case of progressive multifocal leukoencephalopathy (PML) without prior natalizumab use

14. Inspections

14.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.

Request for GMP inspections: **For adoption**

14.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.

Request for GCP inspections: **For adoption**

14.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.

Request for Pharmacovigilance inspections: **For adoption**

14.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.

Request for GLP inspections: **For adoption**

15. Innovation Task Force

15.1. Minutes of Innovation Task Force: For information

15.2. Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 of the European Parliament and of the Council

Request from EDQM for EMA scientific Opinion under procedure Art. 57 (1)J of Regulation (EC) No 726/2004 • CHMP scientific opinion: **For adoption**
Request from DG Internal Market, Industry, Entrepreneurship and SME's, Unit I/4 (ex-SANCO B2) under procedure Art. 57 (1) of Regulation (EC) No 726/2004 for EMA scientific Opinion • Final CHMP scientific opinion: **Adopted by written procedure**

15.4. Nanomedicines activities

16. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 9-12 march 2015. Table of conclusions: **For information**	
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*

17. Satellite Groups

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 23-25 March 2015: **For information**

CMDh question to CHMP (PKWP) regarding potential risk of longer half-life of acitretin,

- PKWP response: **For adoption**

CMDh question to CHMP (BSWP) dated 10 March 2015 regarding bioequivalence study used in aripiprazole generic application procedures.

- BSWP response: **For adoption**

18. Other Committees

18.1. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 17-19 March 2015: **For information**

18.2. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 9-12 March 2015: **For information**

18.3. Paediatric Committee (PDCO)

PIPs reaching D30 at March 2015 PDCO: **For information**

Report from the PDCO meeting held on held on 18-20 March 2015: **For information**

18.4. Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 19-20 March 2015: **For information**

19. Invented name issues

20. Any other business

Revision of the Ph. Eur. Monograph on Human Plasma (pooled and treated for virus inactivation) (1646) 'S/D Plasma': **For adoption and transmission to CMDh**

Report from BWP drafting group (EMA/CHMP/BWP/102099/2015)

Update on activities related to revised RMP Assessment process in 2015

Implementation of the revised RMP assessment process: **For discussion**

EU Network Training Centre - website containing the first catalogue of trainings accessible to the entire Network (http://euntc.eudra.org/index.html)

Agenda of the Strategic Review & Learning CHMP/CAT meeting under Latvian EU presidency to be held in Ljubljana, Slovenia, from 26 - 28 May, 2015: **For information**

CHMP 2015 work plan (EMA/394100/2014)**: For adoption**

Peer Review: Best Practice (EMA/742633/2014)**: For adoption**

Risk Assessment Template

- Background note for March CHMP: **For discussion**
- Explanatory Notes for Pilot Procedure: **For adoption**

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis (EMA/CHMP/771815/2011): **For adoption**

Overview of external comments received (EMA/CHMP/154617/2015): **For information**

Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products (EMA/CAT/80183/2014): **For adoption for external consultation until end of July 2015**

Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis: **For 2nd release for public consultation**

List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 23-26 March 2015 meeting.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.